MRKR
Income statement / Annual
Last year (2024), Marker Therapeutics, Inc.'s total revenue was $6.59 T,
an increase of 199,058,047.17% from the previous year.
In 2024, Marker Therapeutics, Inc.'s net income was -$10.73 M.
See Marker Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$6.59 T |
$3.31 M |
$9.00 M |
$1.24 M |
$466,785.00 |
$213,194.00 |
$205,994.00 |
$183,064.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$10.42 M
|
$3.68 M
|
$3.16 M
|
$18.88 M
|
$12.76 M
|
$124.00 M
|
$5.25 M
|
$0.00
|
$0.00
|
| Gross Profit |
$6.59 T
|
-$7.11 M
|
$5.32 M
|
-$1.92 M
|
-$18.41 M
|
-$12.55 M
|
-$123.79 M
|
-$5.07 M
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
1
|
-2.15
|
0.59
|
-1.55
|
-39.45
|
-58.87
|
-600.95
|
-27.68
|
0
|
0
|
| Research and Development Expenses |
$13.47 T
|
$10.42 M
|
$26.14 M
|
$27.79 M
|
$18.88 M
|
$12.76 M
|
$124.00 M
|
$5.25 M
|
$3.80 M
|
$1.71 M
|
| General & Administrative Expenses |
$4.24 T
|
$7.48 M
|
$12.82 M
|
$12.92 M
|
$10.47 M
|
$9.98 M
|
$24.38 M
|
$6.41 M
|
$4.69 M
|
$4.45 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.24 T
|
$7.48 M
|
$12.82 M
|
$12.92 M
|
$10.47 M
|
$9.98 M
|
$24.38 M
|
$6.41 M
|
$4.69 M
|
$4.45 M
|
| Other Expenses |
$0.00
|
-$10.42 M
|
-$232,974.00
|
-$2.41 M
|
$0.00
|
$0.00
|
$116.05 M
|
-$183,064.00
|
$1,828.00
|
$0.00
|
| Operating Expenses |
$17.71 T
|
$7.48 M
|
$38.96 M
|
$40.72 M
|
$29.35 M
|
$22.74 M
|
$148.38 M
|
$11.48 M
|
$8.26 M
|
$6.16 M
|
| Cost And Expenses |
$17.71 T
|
$17.89 M
|
$38.96 M
|
$40.72 M
|
$29.35 M
|
$22.74 M
|
$148.38 M
|
$11.48 M
|
$8.26 M
|
$6.16 M
|
| Interest Income |
$437,010.00
|
$539,158.00
|
$248,063.00
|
$5,700.00
|
$148,742.00
|
$1.08 M
|
$253,723.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10,925.00
|
| Depreciation & Amortization |
-$11.12 T
|
$2.79 M
|
$3.68 M
|
$3.16 M
|
$1.08 M
|
$286,582.00
|
$148.17 M
|
$11.48 M
|
$8.49 M
|
-$27.90 M
|
| EBITDA |
-$11.12 T |
-$11.79 M |
-$19.79 M |
-$36.32 M |
-$27.63 M |
-$22.03 M |
-$147.97 M |
-$11.30 M |
$6.04 M |
-$34.06 M |
| EBITDA Ratio |
-1.69
|
-3.56
|
-2.2
|
-29.25
|
-59.19
|
-103.33
|
-718.3
|
-61.71
|
0
|
0
|
| Operating Income Ratio |
-1.69
|
-4.4
|
-3.33
|
-31.79
|
-61.88
|
-105.67
|
-719.3
|
-63.71
|
0
|
0
|
| Total Other Income/Expenses Net |
$437.01 B
|
$539,158.00
|
$15,089.00
|
-$2.40 M
|
$179,742.00
|
$1.10 M
|
$213,723.00
|
$497,865.00
|
$6.04 M
|
-$27.91 M
|
| Income Before Tax |
-$10.68 T
|
-$14.04 M
|
-$29.93 M
|
-$41.88 M
|
-$28.71 M
|
-$21.43 M
|
-$147.96 M
|
-$10.98 M
|
-$2.46 M
|
-$34.07 M
|
| Income Before Tax Ratio |
-1.62
|
-4.24
|
-3.32
|
-33.73
|
-61.5
|
-100.51
|
-718.26
|
-59.99
|
0
|
0
|
| Income Tax Expense |
$49.95 B
|
$3,675.00
|
-$15,089.00
|
-$5,700.00
|
-$179,742.00
|
-$1.10 M
|
-$213,723.00
|
-$680,929.00
|
-$6.04 M
|
$27.90 M
|
| Net Income |
-$10.73 M
|
-$14.05 M
|
-$29.92 M
|
-$41.87 M
|
-$28.53 M
|
-$20.33 M
|
-$147.96 M
|
-$10.98 M
|
-$2.46 M
|
-$34.07 M
|
| Net Income Ratio |
-0
|
-4.24
|
-3.32
|
-33.72
|
-61.11
|
-95.35
|
-718.26
|
-59.99
|
0
|
0
|
| EPS |
-1.19 |
-1.93 |
-3.58 |
-5.47 |
-6.06 |
-4.46 |
-77.5 |
-11.62 |
-3.56 |
-93.02 |
| EPS Diluted |
-1.19 |
-1.93 |
-3.58 |
-5.47 |
-6.06 |
-4.46 |
-77.5 |
-11.62 |
-3.31 |
-93.02 |
| Weighted Average Shares Out |
$8.98 M
|
$8.81 M
|
$8.35 M
|
$7.65 M
|
$4.70 M
|
$4.56 M
|
$1.91 M
|
$945,348.00
|
$688,989.00
|
$366,225.00
|
| Weighted Average Shares Out Diluted |
$8.98 M
|
$8.81 M
|
$8.35 M
|
$7.65 M
|
$4.70 M
|
$4.56 M
|
$1.91 M
|
$945,348.00
|
$742,099.00
|
$366,225.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
